Yamazaki Haruhiko, Toda Soji, Sasaki Rika, Saito Aya
Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama City, Kanagawa, Japan.
Department of Surgery, Yokohama City University School of Medicine, Yokohama City, Kanagawa, Japan.
Endocrine. 2025 Jan;87(1):188-195. doi: 10.1007/s12020-024-03974-2. Epub 2024 Jul 28.
In the 9th edition of general rules for the description of thyroid cancer (GRDTC), the N factor was subdivided according to the maximum diameter of metastatic lymph nodes, presence of extra-nodal extension (ENE), and location of mediastinal lymph nodes. This study aimed to investigate the clinical usefulness of the 9th GRDTC risk stratification in papillary thyroid carcinoma (PTC) patients with lymph node metastasis.
A total of 703 PTC patients with lymph node metastasis who underwent initial thyroidectomy at our institution between January 2000 and October 2023 were included.
Among the 703 patients with PTC, the 10-year cause specific survival rates of patients with pN1a-1 (n = 383), pN1a-2 (n = 13), pN1b-1 (n = 234), and pN1b-2 (n = 73) were 97.9%, 100%, 95.4%, and 76.2%, respectively (p < 0.001). Therefore, the pN1b-2 classification identified patients with a worse prognosis among those with pN1b. Among the 664 patients with M0 PTC, the 10-year disease free survival (DFS) rates of the patients with pN1a-1 (n = 378), pN1a-2 (n = 13), pN1b-1 (n = 215), and pN1b-2 (n = 58) were 86.9%, 62.5%, 79.9%, and 59.4%, respectively (p < 0.001). The pN1b-2 category was associated with worse DFS in pN1b patients.
The 9th edition of the GRDTC may be useful for stratifying the prognosis of patients with PTC. The risk assessment of PTC-related death and recurrence will be more accurate by considering the size of lymph node metastasis and ENE in GRDTC.
在《甲状腺癌描述总则》第9版(GRDTC)中,N因子根据转移性淋巴结的最大直径、结外扩展(ENE)的存在以及纵隔淋巴结的位置进行了细分。本研究旨在探讨第9版GRDTC风险分层在伴有淋巴结转移的甲状腺乳头状癌(PTC)患者中的临床实用性。
纳入2000年1月至2023年10月期间在本机构接受初次甲状腺切除术的703例伴有淋巴结转移的PTC患者。
在703例PTC患者中,pN1a-1(n = 383)、pN1a-2(n = 13)、pN1b-1(n = 234)和pN1b-2(n = 73)患者的10年病因特异性生存率分别为97.9%、100%、95.4%和76.2%(p < 0.001)。因此,pN1b-2分类在pN1b患者中识别出预后较差的患者。在664例M0 PTC患者中,pN1a-1(n = 378)、pN1a-2(n = 13)、pN1b-1(n = 215)和pN1b-2(n = 58)患者的10年无病生存率分别为86.9%、62.5%、79.9%和59.4%(p < 0.001)。pN1b-2类别与pN1b患者较差的无病生存率相关。
第9版GRDTC可能有助于对PTC患者的预后进行分层。通过在GRDTC中考虑淋巴结转移的大小和ENE,对PTC相关死亡和复发的风险评估将更加准确。